Eli Lilly Alzheimer's drug rejected by EU regulator
Indianapolis: Indianapolis-based pharmaceutical giant Eli Lilly has faced a setback as the European Union's drug regulator rejected its Alzheimer's drug, citing that the drug's limited impact on slowing cognitive decline was not large enough to outweigh the risk of serious brain swelling in patients.
"European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued an opinion that does not recommend Eli Lilly and Company’s donanemab be granted marketing authorization for the treatment of early symptomatic Alzheimer's disease. Lilly will seek re-examination by CHMP," the Company stated in a release.
The regulator stated that the drug's small impact on slowing cognitive decline was not large enough to outweigh the risk of serious brain swelling in patients.
“Europeans living with early symptomatic Alzheimer’s disease and their loved ones urgently need additional treatment options. The disappointing CHMP opinion means they must keep waiting,” said Ilya Yuffa, executive vice president and president of Lilly International. “Donanemab has been reviewed and approved in the United States, Japan, China, and other markets. Lilly remains confident in the safety and effectiveness of donanemab and the value it can bring to patients with early symptomatic Alzheimer’s disease. We hope that through the re-examination process, we will be able to continue our discussions with the agency to bring donanemab to the millions of people across Europe suffering from this relentless, fatal disease.”
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.